Identification of orally available naphthyridine protein kinase D inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 15, 2010, Pages 5400-5421

  Meredith, Erik L ^a   Ardayfio, Ophelia ^a   Beattie, Kimberly ^a   Dobler, Markus R ^a   Enyedy, Istvan ^a   Gaul, Christoph ^b   Hosagrahara, Vinayak ^a   Jewell, Charles ^a   Koch, Keith ^c   Lee, Wendy ^a   Lehmann, HansJoerg ^b   Mckinsey, Timothy A ^c   Miranda, Karl ^a   Pagratis, Nikos ^c   Pancost, Margaret ^a   Patnaik, Anup ^a   Phan, Dillon ^c   Plato, Craig ^c   Qian, Ming ^a   Rajaraman, Vasumathy ^a   Rao, Chang ^a   Rozhitskaya, Olga ^a   Ruppen, Thomas ^b   Shi, Jie ^a   Siska, Sarah J ^a   Springer, Clayton ^a   Van Eis, Maurice ^b   Vega, Richard B ^a   Von Matt, Anette ^b   Yang, Lihua ^a   Yoon, Taeyoung ^a   Zhang, Ji Hu ^a   Zhu, Na ^a   Monovich, Lauren G ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Gilead Colorado Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAPHTHYRIDINE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE D; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART HYPERTROPHY; HIGH THROUGHPUT SCREENING; MALE; NONHUMAN; RAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; CELL NUCLEUS; HISTONE DEACETYLASES; ISOENZYMES; MALE; MODELS, MOLECULAR; MUSCLE CELLS; MYOCARDIUM; NAPHTHYRIDINES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C; RATS; RATS, INBRED DAHL; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955352047     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100075z     Document Type: Article

References (39)

1. Chatterjee, K.; Massie, B. Systolic and diastolic heart failure: differences and similarities J. Card. Failure 2007, 13, 569
2. Arai, M.; Koitabashi, N.; Watanabe, A.; Niwano, K.; Matsui, H.; Ohyama, Y.; Kurabayashi, M. Mechanisms that underlie diastolic heart failure and diastolic dysfunction J Card. Failure 2008, 14 (Suppl. 1) S142
3. For WHO mortality data by country or region, see http://www.who.int/ whosis/whostat2006-mortality.pdf.
4. Hill, J. A.; Olson, E. N. Mechanisms of disease: cardiac plasticity N. Engl. J. Med. 2008, 358, 1370-1380
5. Gosse, P. Left ventricular hypertrophy as a predictor of cardiovascular risk J. Hypertens. 2005, 23 (Suppl. 1) S27-S33
6. Devereux, R. B.; Wachtell, K.; Gerdts, E.; Boman, K.; Nieminen, M. S.; Papademetriou, V.; Rokkedal, J.; Harris, K.; Aurup, P.; Dahloef, B. Prognostic significance of left ventricular mass change during treatment of hypertension JAMA, J. Am. Med. Assoc. 2004, 292, 2350-2356
7. Aurigemma, G. P; Zile, M. R.; Gaasch, W. H. Contractile behavior of the left ventricle in diastolic heart failure with emphasis on regional systolic function Circulation 2006, 113, 296-304
8. Frey, N.; Olson, E. N. Cardiac hypertrophy: the good, the bad, and the ugly Annu. Rev. Physiol. 2003, 65, 45-79
9. McKinsey, T. A.; Kass, D. A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface Nat. Rev. Drug Discovery 2007, 6, 617-635
10. Potthoff, M. J.; Olson, E. N. MEF2: A central regulator of diverse developmental programs Development 2007, 134, 4131-4140
11. Kim, Y.; Phan, D.; van Rooij, E.; Wang, D.-Z.; McAnally, J.; Qi, X.; Richardson, J. A.; Hill, J. A.; Bassel-Duby, R.; Olson, E. N. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice J. Clin. Invest. 2008, 118, 124-132
12. Chang, S.; McKinsey, T. A.; Zhang, C. L.; Richardson, J. A.; Hill, J. A.; Olson, E. N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development Mol. Cell. Biol. 2004, 24, 8467-8476
13. Olson, E. N.; Backs, J.; McKinsey, T. A. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation Novartis Found. Symp. 2006, 274 (Heart Failure) 3-19
14. Harrison, B. C.; Roberts, C. R.; Hood, D. B.; Sweeney, M.; Gould, J. M.; Bush, E. W.; McKinsey, T. A. The CRM1 nuclear export receptor controls pathological cardiac gene expression Mol. Cell. Biol. 2004, 24, 10636-10649
15. Fielitz, J.; Kim, M.-S.; Shelton, J. M.; Qi, X.; Hill, J. A.; Richardson, J. A.; Bassel-Duby, R.; Olson, E. N. Requirement of protein kinase D1 for pathological cardiac remodeling Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3059-3063
16. Ha, C. H.; Wang, W.; Jhun, B. S.; Wong, C.; Hausser, A.; Pfizenmaier, K.; McKinsey, T. A.; Olson, E. N.; Jin, Z.-G. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis J. Biol. Chem. 2008, 283, 14590-14599
17. Backs, J.; Backs, T.; Bezprozvannaya, S.; McKinsey, T. A.; Olson, E. N. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4 Mol. Cell. Biol. 2008, 28, 3437-3445
18. Huynh, Q. K.; McKinsey, T. A. Protein kinase D directly phosphorylates histone deacetylase 5 via a random sequential kinetic mechanism Arch. Biochem. Biophys. 2006, 450, 141-148
19. Vega, R. B.; Harrison, B. C.; Meadows, E.; Roberts, C. R.; Papst, P. J.; Olson, E. N.; McKinsey, T. A. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5 Mol. Cell. Biol. 2004, 24, 8374-8385
20. Monovich, L.; Vega, R. B.; Meredith, E.; Miranda, K.; Rao, C.; Capparelli, M.; Lemon, D. D.; Phan, D.; Koch, K. A.; Chapo, J. A.; Hood, D. B.; McKinsey, T. A. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase FEBS Lett. 2010, 584, 631-637
21. Gschwendt, M.; Dieterich, S.; Rennecke, J.; Kittstein, W.; Mueller, H.-J.; Johannes, F.-J. Inhibition of protein kinase C - by various inhibitors. Differentiation from protein kinase c isoenzymes FEBS Lett. 1996, 392, 77
22. Singh, R.; Li, H.; Zhao, H.; Payan, D. G.; Kolluri, R.; Tso, K.; Ramphal, J.; Gu, S. Preparation of Cyclic Amine Substituted Pyrimidinediamines as PKC Inhibitors. WO 2009012421, 2009.
23. Yokoyama, S. AP2 Inhibitor WO 2008088006, 2008.
24. Raynham, T. M.; Hammonds, T. R.; Charles, M. D.; Pave, G. A.; Foxton, C. H.; Blackaby, W. P.; Stevens, A. P.; Ekwuru, C. T. Pyridine Benzamides and Pyrazine Benzamides as PKD Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Diseases, WO 2008074997, 2008.
25. Raynham, T. M.; Hammonds, T. R.; Gilliatt, J. H.; Charles, M. D.; Pave, G. A.; Foxton, C. H.; Carr, J. L.; Mistry, N. S. Aminoethylamino-aryl (AEAA) Compounds as PKD Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of PKD-Mediated Diseases. WO 2007125331, 2007.
26. Gschwendt, M.; Kittstein, W.; Johannes, F.-J. Differential effects of suramin on protein kinase C isoenzymes, a novel tool for discriminating protein kinase C activities FEBS Lett. 1998, 421, 165-168
27. Sharlow, E. R.; Giridhar, K. V.; LaValle, C. R.; Chen, J.; Leimgruber, S.; Barrett, R.; Bravo-Altamirano, K.; Wipf, P.; Lazo, J. S.; Wang, Q. J. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone J. Biol. Chem. 2008, 283, 33516-33526
28. Slater, S. J.; Seiz, J. L.; Cook, A. C.; Stagliano, B. A.; Buzas, C. J. Inhibition of protein kinase C by resveratrol Biochim. Biophys. Acta, Mol. Basis Dis. 2003, 1637, 59-69
29. Haworth, R. S.; Avkiran, M. Inhibition of protein kinase D by resveratrol Biochem. Pharmacol. 2001, 62, 1647-1651
30. Storz, P.; Doppler, H.; Toker, A. Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappaB Mol. Pharmacol. 2004, 66, 870-879
31. Rozengurt, E.; Rey, O.; Waldron, T. Protein kinase D signaling J. Biol. Chem. 2005, 280, 13205-13208
32. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: A network analysis Bioinformatics 2010, 26, 198-204
33. Wang, Q. J. PKD at the crossroads of DAG and PKC signaling Trends Pharmacol. Sci. 2006, 27, 317-323
34. Huynh, Q. K.; McKinsey, T. A. Protein kinase D directly phoshporylates histone deacetylase 5 via a random sequential kinetic mechansim Arch. Biochem. Biophys. 2006, 450, 141-148
35. Izumi, Y.; Matsuoka, M.; Kubo, A.; Nakayama, T.; Fukuda, N.; Watanabe, Y.; Soma, M.; Kanmatsuse, K. Prevention of cardiac hypertrophy by a sub-antihypertensive dose of the - 1-adrenergic antagonist bunazosin in Dahl salt-sensitive rats Hypertens. Res. 1996, 19, 147-150
36. Kobayashi, M.; Machida, N.; Mitsuishi, M.; Yamane, Y. β-Blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure Am. J. Hypertens. 2004, 17, 1112-1119
37. Hardt, S. E.; Sadoshima, J. Negative regulators of cardiac hypertrophy Cardiovas. Res. 2004, 500-509
38. Meredith, E. L.; Beattie, K.; Burgis, R.; Capparelli, M.; Chapo, J.; DiPietro, L.; Gamber, G.; Enyedy, I.; Hood, D. B.; Hosagrahara, V.; Jewell, C.; Koch, K. A.; Lee, W.; Lemon, D. D.; McKinsey, T. A.; Miranda, K.; Pagratis, N.; Phan, D.; Plato, C.; Rao, C.; Rozhitskaya, O.; Soldermann, N.; Springer, C.; Van Eis, M.; Vega, R. B.; Yan, W.; Zhu, Q.; Monovich, L. Identification of potent and selective amidobipyridyl inhibitors of protein kinase D. J. Med. Chem. DOI: 10.1021/jm100076w.
39. Houlihan, W. J.; Cheon, S. H.; Parrino, V. A.; Handley, D. A.; Larson, D. A. Structural modification of 5-aryl-2,3-dihydroimidazo[2,1- a ]isoquinoline platelet activating factor receptor antagonists J. Med. Chem. 1993, 36, 3098-3102